Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) announced new three-year data from the long-term extension (LTE) of the Stelara (ustekinumab) Phase 3 UNIFI study. Investigators designed the trial to evaluate the safety and efficacy of induction and maintenance doses for the treatment in moderate to severely active ulcerative colitis patients.

Johnson & Johnson Posts Positive 3-Year Stelara Data In Ulcerative Colitis

Dominion Energy

Kroger

Target

Vanguard High Dividend Yield ETF

Our stock screener continues to help us find some awesome undervalued dividend stocks to buy. In June, we received $2,341.62 in dividend income.

Dividend Income Summary: Bert's June 2021 Summary

AstraZeneca

BioNTech SE

Moderna

Novavax

Pfizer

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

Vaccine Stocks Fall as Delta Becomes Dominant Variant in US

The European Union countries reportedly ordered nearly 40 million additional doses of the COVID-19 vaccine produced by Johnson & Johnson (NYSE: JNJ), a spokesman for the EU Commission said. EU nations initially ordered 200 million doses of the J&J vaccine and could buy up to another 200 million optional shots under the contract.

Certain European Countries Order 40M Additional J&J COVID-19 Jabs: Reuters

NVIDIA

Costco

QUALCOMM

Texas Instruments

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified NVIDIA Corporation, among others.

NVIDIA Corporation Among Today's Large-Cap Stocks

We believe that the stock price of Johnson & Johnson has more room for growth from its current levels of $166. JNJ stock is up only 10% from the levels of around $150 it was at in mid-February, 2020, before the pandemic led to a steep correction in the stock markets.

Continue To Ride Johnson & Johnson Stock For Higher Levels

Federal regulators on Friday cleared another batch of the main ingredient for Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccine, made at Emergent BioSolutions Inc's (NYSE:EBS) Baltimore facility. The cleared batch can furnish up to 15 million doses of the single-dose shot, Bloomberg reported.

FDA Releases More JNJ's COVID-19 Vaccine Substance From Baltimore Plant

Dollar General

Kellogg

Kimberly-Clark

NextEra Energy

Verizon

Walmart

In times of market turmoil, these types of defensive plays typically experience less dramatic price fluctuations. So, what are some safe harbor stocks to buy ahead of a Fed-induced market maelstrom, consider these seven worthwhile options.

7 Safe Harbor Stocks To Buy Ahead of the Potential Volatility

Altimmune

Alphabet

Walgreens

Wall Street crossed over into the second half of the year, as well as a new month and quarter this week, and the transition was a seamless one.

Wall Street Heads Into H2 With Stocks on a Streak

The European Medicines Agency said Friday it has approved a ramp-up of production at a facility operated by Janssen Biologics V.V., which makes ingredients for the COVID-19 vaccine developed by its parent Johnson & Johnson.

European regulator approves ramp-up of production for ingredients used in J&J vaccine in Europe

The shares of Johnson & Johnson (NYSE:JNJ) are up 0.4% to trade at $166.55 at last check, following news that its single-dose Covid-19 vaccine is effective against the Delta variant, which has been rapidly spreading in Europe, India, and South Africa.

Which Covid-19 Vaccine is Showing Efficacy Against the Delta Variant

Johnson & Johnson said a study showed that its Covid-19 vaccine elicits neutralizing antibody activity against the Delta variant sweeping the globe.

J&J Covid-19 Vaccine Protects Against Delta Variant, Study Says

The Delta variant is already the most dominant strain of the virus in some U.S. states, and that's putting some Americans easing back into “normal” life on edge.

Worries emerge about the Delta variant and the J&J shot. But health officials and preliminary research say the vaccinated are still protected

All available vaccines are mostly more effective against the Delta variant after two doses, and less effective after the first dose.

How Potent Are JNJ & Other COVID-19 Jabs Against Delta Variant?

Is the U.S. Buying Too Many COVID Vaccine Doses?

Shares of Johnson & Johnson (NYSE: JNJ) rose 0.7% in the regular trading session on Thursday and were trading slightly higher in the market session on Friday. What Happened: Johnson & Jonson said late Thursday that its single-shot COVID-19 vaccine showed strong promise against the fast-spreading Delta variant and other emerging strains of the virus.

What's Going On With Johnson & Johnson (JNJ) Stock Today?

NEW BRUNSWICK, N.J., July 1, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants.

Positive New Data for Johnson & Johnson Single-Shot COVID-19 Vaccine on Activity Against Delta Variant and Long-lasting Durability of Response

Caterpillar

Diageo

RELX

Unilever

Investors should focus on ‘dividend aristocrats' that have been able to consistently grow dividends rather than companies with the highest yields, Credit Suisse has advised its clients. Nearly 60% of total returns since 1900 have come from (reinvested) dividends over the past 120 years in the US, the Swiss bank pointedly observed in a note on Thursday.

Invest in ‘dividend aristocrats' and don't be tempted by high yields, says Credit Suisse

Investors could own Johnson & Johnson for its wide moat, immaculate dividend track record, and strong profitability.

Johnson & Johnson: The Market Got It Right

Dr. Vivek Murthy said there is reason to be hopeful that people who received the Johnson & Johnson Covid-19 vaccine may be protected against the delta variant.

U.S. surgeon general says Johnson & Johnson Covid vaccine may protect people against delta variant

Amazon

Visa

These unstoppable stocks won't stop delivering for their shareholders.

3 Buffett Stocks You'll Never Have to Sell

AbbVie

AmerisourceBergen

Cardinal Health

CVS Health

Endo International

McKesson

Rite Aid

Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International Plc (NASDAQ: ENDP), and AbbVie Inc's (NYSE: ABBV) Allergan misleadingly marketed opioid drugs as having a low addiction risk, a lawyer for a New York county told jurors, urging them to hold the companies liable. Jayne Conroy, representing Suffolk County, also said that the drug distributors - AmerisourceBergen Corp (NYSE: ABC), Cardinal Health Inc (NYSE: CAH), and McKesson Corp (NYSE: MCK) failed to report suspicious opioid orders as required.

News for Johnson & Johnson Stock (JNJ)